

Therapeutics Advisory Group Update - Issue 30 – May 2024

All recommendations discussed at the **May** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **May 2024**. Please share within your organisation as appropriate

Commissioning Summary

Commissioning Review – Relugolix-Estradiol-Norethisterone Acetate tablets (Ryeqo®▼) for treatment of uterine fibroids	<ul style="list-style-type: none"> To remain as ADVICE – Specialist Initiation. First three months supplied by specialist as per published guidance document
Commissioning Review - Self-Care – Anaemia in Pregnancy	<ul style="list-style-type: none"> Document to support patients who require iron supplementation in pregnancy, but who would prefer to purchase rather than wait for a prescription. Document supported by the TAG
Commissioning Review - Xonvea (doxylamine/ pyroxidine) for nausea and vomiting in pregnancy	<ul style="list-style-type: none"> To remain Double Red – can be prescribed as a last resort if all other formulary options have been unsuccessful
Commissioning Review - Pulmicort Respules (oral viscous budesonide) for eosinophilic oesophagitis in paediatrics	<ul style="list-style-type: none"> Red Hospital Only Local adaptation of Cambridge and Peterborough guidance document
Commissioning Review - Prosource jelly and Aymes Actagain protein shot	<ul style="list-style-type: none"> Double Red – can be prescribed as a last resort if all other formulary options have been unsuccessful for ACBS criteria only (hypoproteinaemia) BLACK for all other indications
Commissioning Review – Nefopam for chronic pain relief	<ul style="list-style-type: none"> Double Red – can be prescribed as a last resort if all other formulary options have been unsuccessful
Commissioning Review - Risankizumab for moderate to severe active Crohn's disease as per TA888	<ul style="list-style-type: none"> Red Hospital Only
Commissioning Review - Sodium zirconium cyclosilicate for acute and persistent hyperkalaemia as per TA599	<ul style="list-style-type: none"> Acute use extended to include moderate hyperkalaemia K>6.0 Persistent use updated from BLACK to ADVICE – Specialist initiation
Commissioning Review - Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) TA648	<ul style="list-style-type: none"> BLACK – Not Commissioned. No prescribing in primary or secondary care.
Commissioning Review - Paliperidone (Invega) for mental health conditions	<ul style="list-style-type: none"> Red Hospital Only for all formulations

Netformulary Updates

- **DROPtomic®** - alternative cost effective formulation of PF sodium chloride 5% eye drops. Can be used with contact lenses
- **Ocufresh-C®** - alternative cost-effective formulation of hypromellose 0.3% eye drops. Can be used with contact lenses
- **VIZhyal 0.1% eye drops** PF as an alternative cost-effective product of sodium hyaluronate PF
- **Aactive HA® PF 0.2% eye drops** and **VIZhyal® 0.2% PF eye drops** as alternative cost-effective products to sodium hyaluronate **0.2% PF eye drops**

Shared Care Updates

Stimulants for Attention Deficit Hyperactivity Disorder (ADHD) in Children & Young People aged at least 6 years old

- Updates supported by TAG
- Document published on KNoW [here](#)

NICE Guidance – acknowledged by the TAG

NG239 – March 2024 - Vitamin B12 deficiency in over 16s: diagnosis and management	NG241 – March 2024 Ovarian cancer: identifying and managing familial and genetic risk	NG240 – March 2024 Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
NG191 – March 2021, updated March 2024 COVID-19 rapid guideline: managing COVID-19	NG73 – September 2017, updated April 2024 Endometriosis: diagnosis and management	NG51 – July 2016, updated March 2024 Suspected sepsis: recognition, diagnosis and early management
NG195 – April 2021, updated March 2024 Neonatal infection: antibiotics for prevention and treatment	NG122 – March 2019, updated March 2024 Lung cancer: diagnosis and management	NG137 – September 2019, updated April 2024 Twin and triplet pregnancy

NICE Technology Appraisals – ICB Commissioning Responsibility

TA956- March 2024 Etrasimod (Velsipity®) for treating moderately to severely active ulcerative colitis in people aged 16 and over	Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care
TA953 – March 2024 Fluocinolone acetonide intravitreal implant (Iluvien®) for treating chronic diabetic macular oedema	
TA955 – March 2024 Dupilumab for treating moderate to severe prurigo nodularis	BLACK – not commissioned. Not for prescribing in primary or secondary care
TA878 – March 2023, updated March 2024 Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	Commissioning remains unchanged. The NHS will expand access to nirmatrelvir plus ritonavir to more groups (details in the guidance)
TA958 – March 2024 Ritlecitinib (Litfulo®) for treating severe alopecia areata in people 12 years and over	BLUE - NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available.

NICE Technology Appraisals – NHS England Commissioning Responsibility

<p>TA954 – March 2024 Epcoritamab (Tepkinly®) for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments</p>	<p>RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
<p>TA957 – March 2024 Momelotinib (Omjjara®) for treating myelofibrosis-related splenomegaly or symptoms</p>	
<p>TA959 – March 2024 Daratumumab (Darzalex®) in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis</p>	
<p>TA962 – March 2024 Olaparib (Lynparza®) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy</p>	
<p>TA963 – April 2024 Dostarlimab (Jemperli®) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency</p>	
<p>TA964 – April 2024 Cabozantinib (Cabometyx®) with nivolumab for untreated advanced renal cell carcinoma</p>	

NICE Technology Appraisals – Terminated Appraisals

<p>TA960 – March 2024 Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders</p>	<p>BLACK – not commissioned. Not for prescribing in primary or secondary care</p>
<p>TA965 – March 2024 Human alpha1-proteinase inhibitor for treating emphysema</p>	
<p>TA961 – March 2024 Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease</p>	
<p>TA966 – April 2024 Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer</p>	

Reminder

- Knowledge NoW is live and can be accessed [here](#) Please send any comments/queries to the inbox with **'KNoW'** in the subject line - nwcb.medsqueries@nhs.net
- Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates

Useful Information

Next meeting	Wednesday 3rd July 2024
Deadline for agenda submissions	Tuesday 25th June 2024